AstraZeneca shares slide while Gilead Sciences soar amid merger rumours
Shares in Gilead Sciences climbed higher on Monday, while UK-based AstraZeneca saw its stock take a tumble after reports of a possible merger between the two companies emerged.
Shares in Gilead Sciences climbed 3% higher in early morning trading on Monday, while AstraZeneca stock closed 2% lower after reports of a possible merger between the two companies surfaced.
Gilead Services share price rally was short-lived, however, with the stock trading flat at $77 at the time of publication, while AstraZeneca closed at £82 per share on Monday.
AstraZeneca-Gilead Sciences negotiations fall flat
Last month, the British drug maker AstraZeneca approached the biotechnology company, which is trailing its drug remdesivir as a potential treatment for the Covid-19 virus, only to have its merger proposal shot down.
AstraZeneca’s shares took a tumble in the wake of the deal rumours, with investors left scratching their heads as to why the British drug maker would entertain a deal with such a poor rationale and require a significant amount of capital to complete.
If the merger did go ahead it would combine the two companies efforts in finding a cure for the coronavirus. However, it would likely create a politically sensitive situation whereby each company’s government’s would seek control over any potential vaccine or treatment created by the pair.
‘[Gilead] may be on the verge of having one of the fastest growing products in the industry, if they can successfully establish profitable commercial pricing for remdesivir,’ SVB Leerink analyst Geoffrey Porges told Reuters..
AstraZeneca: JP Morgan reiterates ‘overweight’ rating
Analysts at JP Morgan remain optimistic about AstraZeneca, with the US-based investment bank reiterating its ‘overweight’ rating for the stock and issuing a target price of £84.27 per share, implying a potential upside of 2.7%.
JP Morgan said that there was a ‘low probability’ of a merger between AstraZeneca and Gilead Sciences, with the US government likely resistant to the company being acquired by a foreign drug maker.
However, the investment bank did concede that if the deal were to go ahead it would support AstraZeneca’s earnings.
‘We calculate this would be highly accretive to Astra earnings in the medium-term, with around 50% core EPS accretion in 2021, 40% accretion in 2022, accretion in the 20s in 2023-25,’ JP Morgan said.
‘In addition, to the EPS accretion, depending on the offer structure, the deal could also allow Astra to de-lever, which in turn could provide more room for pipeline in-licensing.’
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Act on stock opportunities today
Go long or short on thousands of international stocks with CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
